Fenofibric acid: In combination therapy in the treatment of mixed dyslipidemia

American Journal of Cardiovascular Drugs

Volumn 9, Issue 6, 2009, Pages 401-409

  Yang, Lily P H ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COUMARIN ANTICOAGULANT; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; FLUINDOSTATIN; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEPRAZOLE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG;

BACKACHE; BILE DUCT OBSTRUCTION; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DIET THERAPY; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEADACHE; HEART INFARCTION; HUMAN; INCIDENCE; INTERVERTEBRAL DISK HERNIA; LIPID METABOLISM; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; SYNCOPE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTILIPEMIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PPAR ALPHA; PROCETOFEN;

EID: 71149117118     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11203920-000000000-00000     Document Type: Review

References (26)

1. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation 2002 Dec 17; 106 (25): 3143-3421
2. Cheung BMY, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009 May; 122 (5): 443-453
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004 Oct; 27 (10): 2444-2449
4. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 Dec; 91 Suppl. 5: v1-52
5. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clin Ther 2008 Feb; 30 (2): 294-306
6. Quilliam BJ, Perez HE, Andros V, et al. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharm 2004 May-Jun; 10 (3): 244-250
7. Rajagopalan S, Alemao E, Finch L, et al. Impact of new Joint British Society's (JBS 2) guidelines on prevention of cardiovascular disease: Evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr Med Res Opin 2007 Aug; 23 (8): 2027-2034
8. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008 Oct; 17 (10): 1599-1614
9. Keating GM, Croom KF. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67 (1): 121-153
10. US FDA. Trilipix (fenofibric acid) oral delayed release capsules: US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2008/022224s000lbl.pdf [Accessed 2009 Oct 20]
11. Abbott Laboratories. Frequently asked questions about TRILIPIX [online]. Available from URL: http://www.trilipix.com/AboutTrilipix/FAQs.aspx [Accessed 2009 Oct 20]
12. Keating GM, Ormrod D. Micronised fenofibrate: An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62 (13): 1909-1944
13. Israelian-Konaraki Z,Reaven PD. Peroxisome proliferator-activated receptoralpha and atherosclerosis: From basic mechanisms to clinical implications. Cardiol Rev 2005 Sep-Oct; 13 (5): 240-246 (Pubitemid 41197252)
14. Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPARa): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009 Jul; 205 (1): 1-8
15. Zhu T, Awni WM, Hosmane B, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009 Jan; 49 (1): 63-71
16. Abbott Laboratories. Tricor (fenofibrate tablets): US prescribing information [online]. Available from URL: http://www.rxabbott.com/pdf/tricorpi. pdf [Accessed 2009 Oct 20]
17. Tojcic J, Benoit-Biancamano MO, Court MH, et al. In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes. Drug Metab Dispos 2009 Nov; 37 (11): 2236-2243
18. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009 Feb 15; 103 (4): 515-522
19. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 2009 May; 204 (1): 208-215
20. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Am Heart J 2009 Jan; 157 (1): 195-203
21. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Invest 2008; 28 (10): 625-634
22. Bays HE, Jones PH, Mohiuddin M, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008 Dec; 2 (6): 426-435
23. Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol 2009 Apr; 3 (2): 125-137
24. GoldbergAC,Robinson JG, PepineCJ, et al. Fenofibric acid in combinationwith statins improves multiple lipid parameters in women with mixed dyslipidemia [abstract no. 1012-85]. J Am Coll Cardiol 2009Mar 10; 53 Suppl. 1 (10): A202
25. Sleep DJ, Goldberg AC, Setze CM, et al. Efficacy of fenofibric acid in combination with atorvastatin in patients with type 2 diabetes mellitus and mixed dyslipidaemia [abstract no. 1248]. 45th Annual Meeting of the European Association for the Study of Diabetes; 2009 Sep 30; Vienna
26. Rosenson RS, Carlson DM, Kelly MT, et al. Simultaneous attainment of lipid targets with the combination of fenofibric acid and rosuvastatin in patients with type 2 diabetes mellitus [abstract no. 936-P]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)